Somatropin - Eli Lilly

Drug Profile

Somatropin - Eli Lilly

Alternative Names: Humatrope; Hutrope; LY 137998; Umatrope

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly
  • Developer Amylin Pharmaceuticals; Eli Lilly
  • Class Growth hormones; Hormonal replacements
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Cachexia; Growth disorders; Prader-Willi syndrome; Short bowel syndrome; Short stature; Somatotropin deficiency; Turner's syndrome

Most Recent Events

  • 16 Jul 2013 Biomarkers information updated
  • 02 Oct 2012 Launched for Cachexia (in patients with AIDS) in India (SC) before October 2012
  • 02 Oct 2012 Launched for Prader-Willi syndrome in Belgium (SC) before October 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top